Dynamic use of tumor markers, rationale-clinical applications and pitfalls

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2279-2284

  Gion, Massimo ^a,b   Mione, Riccardo ^a   Barioli, Paola ^a   Dittadi, Ruggero ^a  

^a Regional General Hospital   (Italy)

^b Ospedale Civile SS   (Italy)

Author keywords

Decision criteria; Kinetic; Tumor markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; FOLLOW UP; GERM CELL TUMOR; HALF LIFE TIME; HUMAN; MATHEMATICAL ANALYSIS; MEDICAL DECISION MAKING; METASTASIS; OVARY CANCER; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029837662     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Galen RS and Gambino SR: Beyond normality: the predictive value and efficiency of medical diagnoses. New York, John Wiley, 1975.
2. Metz CE: Basic principles of ROC analysis: Semin Nncl Med 8: 283-298, 1978
3. Bates SE and Longo DL: Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev 12: 163-207, 1985.
4. Gion M, Mione R and Bruscagnin G: Clinical use of tumor markers. Current strategies for decision making. In: Up dating on tumor markers in tissues and biological fluids. Basic aspects and clinical applications (Ballesta AM, Torre GC, Bombardieri E. Gion M and Molina R eds). Torino. Minerva Medica. 1993, 179-193.
5. Carter HB, Pearson JD, Metter J, Brant LJ, Chan DW, Andres R, Fozard JL et al: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
6. Catalona WJ and Smith DS: Comparison of different serum prostate-specific antigen measures for early prostate cancer detection. Cancer 74: 1516-1518, 1994.
7. Mione R, Barichello M, Sartorello P, Leon A, Barioli P and Gion M: Third generation PSA: ultrasensitive or ultraprecise assay? Int J Biol Markers, 1995.
8. Rizkallah T, Gurpide E and Vande Weile RL: Metabolism of HCG in man. J Clin Endocrinol 29: 92-100, 1969.
9. Bartlett NL, Freiha FS and Torti FM: Serum markers in germ cell neoplasm. Germ Cell Neoplasm 5(6): 1245-1260, 1991.
10. Lange P, Vogelzang NJ, Goldman A et al: Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128: 708-711, 1982.
11. Semjonow A, Hamm M and Rathert P: Halt-life of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment? Eur Urol 21: 200-205, 1992.
12. Frazier HA, Robertson JE, Humphrey PA and Paulson DF: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 149: 516-518, 1993.
13. Van der Burg MEL, Lammes FB, van Putten WIJ and Stoter G: Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 30: 307-312, 1988.
14. Buller RE, Berman ML, Bloss JD, Manetta A and Di Saia PJ: CA125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol 165: 360-367, 1991.
15. Yedema CA, Kenemans P, Voorhorst F, Bon G, Sehijf C, Beex L, Verstraeten A and Hilgers J: CA 125 halt-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 67: 1361-1167, 1993.
16. Canney PA, Moore M, Wilkinson PM and James RD: Ovarian cancer anligen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50: 765-769, 1984.
17. Lavin PT, Knapp RC, Malkasian G, Whitneyn CW, Berek JC, Bast RC: CA125 for the monitoring of ovarian carcinoma during primary therapy: Obstet Gynecol 69: 223-227, 1987.
18. Pizzocaro G, Zanoni F, Salvioni R et al. Difficulties of a surveillance study omitting retroperitoneal lymphadencetomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 138: 1393-1396, 1987.
19. Yedema CA, Kenemans P, Thomas CM, Massuger LF, Wobbes T, Verstraeten R, van Kamp GJ and Hilgers J: CA125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cyloreductive surgery. Br J Cancer 67: 1361-1367, 1993.
20. Buller RE, Manetta A, Bloss JD, DiSaia PJ and Berman ML: Does intraperitoneal CA125 reflect disease status? Gynecol Oncol 40: 66-69, 1991.
21. Talbot RW, Jacobsen DJ, Nagorney DM, Malkasian GD and Ritts RE: Temporary elevation of CA125 alter abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 168: 407-412, 1989.
22. van Der Zee AGJ, Duk JM, Aalders JG, Boontje AH, Ten Hoor KA and De Bruijin HWA: The effect of abdominal surgery on the serum concentration of the tumor-associated antigen CA125. Br J Obstet Gynecol 97: 934-938, 1990.
23. Williams MP, Husband JE and Heron CW: Stage I nonseminomatous germ cell tumors of the testis: radiologic follow-up after orchidectomy. Radiology 164: 671-674, 1987.
24. Seckl MJ, Rustin GJS and Bagshawe KD: Frequency of serum tumor marker monitoring in patients with non-seminomatous germ cell tumours. Br J Cancer 61: 916-918, 1990.
25. Lange PH, Ercole CJ, Lightner DJ, Fraley, EE and Vessella R: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J of Urol 141: 873-879, 1989.
26. Graves HCB: Nonprostatic sources of Prostate Specific antigen: a steroid hormone-dependent phenomenon? Clin Chem 41: 7-9, 1995.
27. Fraser CG: The application of theoretical goals based on biological variation data in proficiency testing. Arch Pathol Lab Med 112, 404-415, 1988.
28. Browning MCK and McFarlane NP: Objective interpretation of results for tumor markers. J Nucl Med Allied Sci 34(Suppl to No.3): 89-91, 1990.
29. Sölétormos G, Nielsen D, Schioler V, Skovsgaard T and Dombernowsky P: Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow up. Eur J Cancer 28A(4/5): 845-850, 1992.
30. Sölétormos G, Nielsen D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT and Dombernowsky P: A novel method for monitoring high-risk breast cancer with tumor markers: CA15.3 compared to CEA and TPA. Annals Oncology 4: 861-869, 1993.
31. Gion M, Cappelli G, Barioli P, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli R and Gulisano M: Variability of tumor markers in the follow-up of patients radically resected for breast cancer. Tumor Biol 14: 325-333, 1993.
32. Gion M, Cappelli G, Mione R, Pistorello M, Meo S, Vignati G, Fortunato A and Saracchini S: Evaluation of critical differences of CEA and CA 15.3 levels in serial samples from patients operated for breast cancer. Int J Biol Markers 9 (3): 135-139, 1994.
33. Gion M, Fila G, Biasioli R, Vignati G, Mione R, Saracchini S, Rinaldi E, Testa E and Bruscagnin G: Kinetic use of tumor markers in the follow-up of patients operated for primary breast cancer. J Nucl Med Allied Sci 34(4): 1-7, 1990.
34. Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L: Evaluation of serum CA15.3 determination with CEA and TPA in the post-operative follow up of breast cancer patients. Br J Cancer 64: 154-158, 1991.
35. Fenig E, Nordenberg J, Regev D, Lurie H and Sulkes A: Does MCA contribute to the follow-up of breast cancer patients by CA15.3? Int J Oncol 1: 547-549, 1992.
36. Miserez AR, Günes I, Müller-Brand J, Walther E, Fridrich R and Macke H: Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA15.3. Eur J Cancer 27(2): 126-131, 1991.
37. Jäger W: The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Eur J Cancer Prev 2(3): 133-139, 1993.
38. Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bogni A, Maffioli L, Saccani Jotti G, Bassetto MA, Zurrida S and Costa A: CA15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 29A(1): 144-146, 1993.
39. Vizcarra E, Lluch A, Cibrian R, Jarque F and Garciaconde J: CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Oncology 51: 491-496, 1994.
40. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M and Ballesta AM: Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36(1): 41-48, 1995.
41. Crippa F, Bombardieri E, Seregni E et al: Single determination of CA15.3 and bone seintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Maed 36: 52-55, 1992.
42. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA and Tangen C: An evaluation of the Carcinoembryonic Antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270: 943-947, 1993.
43. Fletcher RH: Carcinoembryonic antigen. Ann Intern Med 104: 66-73, 1986.
44. Ghezzi P, Magnanini S, Rinaldini M, Berardi F, DiBiagio G, Testore F, Tavoni N, Schittulli F, D'Amico C, Pedicini T et al: The impact of follow-up testing on survival and health related quality of life in breast cancer patients. A multicentre randomized controlled trial. JAMA 271: 1587-1592, 1994.
45. Del Turco MR, Palli D, Cariddi A et al: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized triai. JAMA 271: 1593-1598, 1994.
46. Jäger W, Ostrowski M, Krämer S and Lang N: Erlangen tumor marker study on breast cancer. In J Tumor Marker Oncology, abstract for the 10th International Conference on human tumor markers 8: 50, 1993.
47. August DA, Ottow RT and Sugarbaker PH: Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3: 303-324, 1984.
48. Dentsman F, Rosen L, Khubchandani IT, Sheets JA, Stasik JJ and Riether RD: Comparing predictive decision rules in postoperative CEA monitoring. Cancer 58: 2089-2095, 1986.
49. Lavin PT, Day J, Holyoke D, Mittelman A and Chu TM: Statistical evaluation of baseline and follow up Carcinoembryonic Antigen in patients with resectable colorectal carcinoma. Cancer 47: 823-826, 1981.
50. Minton JP, Hoehn JL, Gerber DM et al: results of a 400-patient Carcinoembryonic Antigen second-look colorectal cancer study. Cancer 55: 1284-1290, 1985.
51. Kievit J and Van de Velde CJH: Utility and cost of Carcinoembryonic Antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer 65: 2580-2587, 1990.
52. Northover J. Carcinoembryonic antigen and recurrent colorectal cancer. Gut 27: 117-122, 1986.
53. Steele G Jr, Ellenberg S, Rammins K et al: CEA monitoring among the patients in multi-istitutional adjuvant G.I. therapy protocols. Ann Surg 96: 162-169, 1982.
54. Boey J, Cheung HC, Lai CK and Wang J: A prospective evaluation of serum CEA levels in the management of colorectal carcinoma. Word J Surg 8: 279-286, 1984.
55. van Dalen A: TPS in breast cancer - A comparative study with carcynoembryonic antigen and CA 15.3. Tumor Biol 13: 10-17, 1992.
56. Einarsson R: TPS - A cytokeratin marker for therapy control in breast cancer. Scand J Clin Lab Invest 221: 113-115, 1995.
57. Robertson JFR: Abstracts. The role of serum tumor markers in breast cancer. The Breast 4: 62-63, 1995.
58. Toner GC, Geller NL, Tan C, Nisselbaum J and Bosl GJ: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50: 5904-5910, 1990.
59. Hogberg T and Kagedal B: Serum half-life of the tumor marker CA125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 69: 423-429, 1990.
60. Markowska J, Kopozynski Z, Manys G and Szwierski Z: CA125 in monitoring chemotherapy of patients with ovarian cancer: early response to treatment. Neoplasma 37: 687-692, 1990.
61. Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RCF, Wilkinson P, Cruickshank D, McAllister EJ, Redman CWE, Parker D, Scotts IV, Slevin ML and Roulston JE: The prognostic value of serum CA125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Working Party on gynaecological cancer. Int J Gynecol Cancer 3: 285-292, 1993.